Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309235575> ?p ?o ?g. }
- W4309235575 abstract "Current therapies for HER2-positive breast cancer have limited efficacy in patients with triple-positive breast cancer (TPBC). We conduct a multi-center single-arm phase 2 trial to test the efficacy and safety of an oral neoadjuvant therapy with pyrotinib, letrozole and dalpiciclib (a CDK4/6 inhibitor) in patients with treatment-naïve, stage II-III TPBC with a Karnofsky score of ≥70 (NCT04486911). The primary endpoint is the proportion of patients with pathological complete response (pCR) in the breast and axilla. The secondary endpoints include residual cancer burden (RCB)-0 or RCB-I, objective response rate (ORR), breast pCR (bpCR), safety and changes in molecular targets (Ki67) from baseline to surgery. Following 5 cycles of 4-week treatment, the results meet the primary endpoint with a pCR rate of 30.4% (24 of 79; 95% confidence interval (CI), 21.3-41.3). RCB-0/I is 55.7% (95% CI, 44.7-66.1). ORR is 87.4%, (95% CI, 78.1-93.2) and bpCR is 35.4% (95% CI, 25.8-46.5). The mean Ki67 expression reduces from 40.4% at baseline to 17.9% (P < 0.001) at time of surgery. The most frequent grade 3 or 4 adverse events are neutropenia, leukopenia, and diarrhoea. There is no serious adverse event- or treatment-related death. This fully oral, chemotherapy-free, triplet combined therapy has the potential to be an alternative neoadjuvant regimen for patients with TPBC." @default.
- W4309235575 created "2022-11-25" @default.
- W4309235575 creator A5000135673 @default.
- W4309235575 creator A5005079956 @default.
- W4309235575 creator A5005974424 @default.
- W4309235575 creator A5012450299 @default.
- W4309235575 creator A5014394467 @default.
- W4309235575 creator A5017100408 @default.
- W4309235575 creator A5018093835 @default.
- W4309235575 creator A5023214008 @default.
- W4309235575 creator A5024096604 @default.
- W4309235575 creator A5026242514 @default.
- W4309235575 creator A5031259441 @default.
- W4309235575 creator A5033373412 @default.
- W4309235575 creator A5036269926 @default.
- W4309235575 creator A5040247437 @default.
- W4309235575 creator A5043170409 @default.
- W4309235575 creator A5049341927 @default.
- W4309235575 creator A5052629282 @default.
- W4309235575 creator A5055551987 @default.
- W4309235575 creator A5059916524 @default.
- W4309235575 creator A5064046304 @default.
- W4309235575 creator A5066990241 @default.
- W4309235575 creator A5067920264 @default.
- W4309235575 creator A5068038838 @default.
- W4309235575 creator A5068979528 @default.
- W4309235575 creator A5070293749 @default.
- W4309235575 creator A5071675004 @default.
- W4309235575 creator A5072270419 @default.
- W4309235575 creator A5074182099 @default.
- W4309235575 creator A5076476567 @default.
- W4309235575 creator A5076665137 @default.
- W4309235575 creator A5082727730 @default.
- W4309235575 creator A5086854382 @default.
- W4309235575 creator A5088470075 @default.
- W4309235575 date "2022-11-17" @default.
- W4309235575 modified "2023-10-17" @default.
- W4309235575 title "A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer" @default.
- W4309235575 cites W1999997611 @default.
- W4309235575 cites W2095861620 @default.
- W4309235575 cites W2096145980 @default.
- W4309235575 cites W2123591186 @default.
- W4309235575 cites W2147299492 @default.
- W4309235575 cites W2147415463 @default.
- W4309235575 cites W2150134401 @default.
- W4309235575 cites W2162489016 @default.
- W4309235575 cites W2299045691 @default.
- W4309235575 cites W2320248812 @default.
- W4309235575 cites W2474228968 @default.
- W4309235575 cites W2768649895 @default.
- W4309235575 cites W2782896696 @default.
- W4309235575 cites W2902672529 @default.
- W4309235575 cites W2912285514 @default.
- W4309235575 cites W2963427879 @default.
- W4309235575 cites W2981209325 @default.
- W4309235575 cites W2981669117 @default.
- W4309235575 cites W2982414110 @default.
- W4309235575 cites W3020482066 @default.
- W4309235575 cites W3056304265 @default.
- W4309235575 cites W3127064904 @default.
- W4309235575 cites W3145417893 @default.
- W4309235575 cites W3185914477 @default.
- W4309235575 cites W319682692 @default.
- W4309235575 cites W3199819343 @default.
- W4309235575 cites W3211241105 @default.
- W4309235575 cites W4220874503 @default.
- W4309235575 cites W4226051140 @default.
- W4309235575 cites W4243643326 @default.
- W4309235575 doi "https://doi.org/10.1038/s41467-022-34838-w" @default.
- W4309235575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36396665" @default.
- W4309235575 hasPublicationYear "2022" @default.
- W4309235575 type Work @default.
- W4309235575 citedByCount "4" @default.
- W4309235575 countsByYear W43092355752022 @default.
- W4309235575 countsByYear W43092355752023 @default.
- W4309235575 crossrefType "journal-article" @default.
- W4309235575 hasAuthorship W4309235575A5000135673 @default.
- W4309235575 hasAuthorship W4309235575A5005079956 @default.
- W4309235575 hasAuthorship W4309235575A5005974424 @default.
- W4309235575 hasAuthorship W4309235575A5012450299 @default.
- W4309235575 hasAuthorship W4309235575A5014394467 @default.
- W4309235575 hasAuthorship W4309235575A5017100408 @default.
- W4309235575 hasAuthorship W4309235575A5018093835 @default.
- W4309235575 hasAuthorship W4309235575A5023214008 @default.
- W4309235575 hasAuthorship W4309235575A5024096604 @default.
- W4309235575 hasAuthorship W4309235575A5026242514 @default.
- W4309235575 hasAuthorship W4309235575A5031259441 @default.
- W4309235575 hasAuthorship W4309235575A5033373412 @default.
- W4309235575 hasAuthorship W4309235575A5036269926 @default.
- W4309235575 hasAuthorship W4309235575A5040247437 @default.
- W4309235575 hasAuthorship W4309235575A5043170409 @default.
- W4309235575 hasAuthorship W4309235575A5049341927 @default.
- W4309235575 hasAuthorship W4309235575A5052629282 @default.
- W4309235575 hasAuthorship W4309235575A5055551987 @default.
- W4309235575 hasAuthorship W4309235575A5059916524 @default.
- W4309235575 hasAuthorship W4309235575A5064046304 @default.
- W4309235575 hasAuthorship W4309235575A5066990241 @default.
- W4309235575 hasAuthorship W4309235575A5067920264 @default.
- W4309235575 hasAuthorship W4309235575A5068038838 @default.
- W4309235575 hasAuthorship W4309235575A5068979528 @default.